The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for tepotinib (as hydrochloride monohydrate) (Merck Healthcare Pty Ltd)
Active ingredients
tepotinib (as hydrochloride monohydrate)
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
film-coated tablet
Indication
For the treatment of non-small cell lung cancer (NSCLC) with genetic MET alterations
Therapeutic area
Oncology